新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » 意大利合约研究机构CROS NT收购Stat-Tech

意大利合约研究机构CROS NT收购Stat-Tech

来源:生物谷 2013-09-13 22:00

2013年9月13日讯 /生物谷BIOON/ --意大利合约研究机构CROS NT收购主要经营医疗器械研发的Stat-Tech公司并登陆美国市场。在这份未透露具体金额的合约中规定,收购完成后,Stat-Tech将作为CROS NT位于美国北卡教堂山的一个分公司。

建立于1996年的Stat-Tech公司曾经参与研发了许多已经获得FDA批准并上市的医疗器械,同时Stat-Tech还涉足小分子药物研发领域。CROS NT的这笔收购案不但将自己的经营领域扩展到了医疗器械领域,还扩大了自己在美国市场的客户群。(生物谷Bioon.com)

详细英文报道:

Italian contract researcher CROS NT has landed in the U.S., snapping up medical device-focused CRO Stat-Tech.

Neither company is disclosing financial details, but the Chapel Hill, NC-based Stat-Tech will become a subsidiary of CROS NT once the deal closes later this month.

Stat-Tech has contributed to numerous medical device trials for FDA clearances and approvals since its foundation in 1996, according to the company, and adding its capabilities to CROS NT's biometrics heft will help the Italian outfit expand its client base, CEO Paolo Morelli said.

"The experience and quality of the Stat-Tech team will add strong value to CROS NT, adding the important area of medical devices to our portfolio and allowing us to improve our services to our existing U.S. customers by being closer to them," Morelli said.

CROS NT's American debut follows its expansion into the U.K. last year, adding to its capacity in Italy and Germany.

Beyond medical devices, Stat-Tech has run trials for biologics and small-molecule drugs, and pairing its might with CROS NT's expertise will help the company grow its market share, co-founder George DeMuth said.

"This move allows us to provide a broader range of services and additional resources to our existing clients and provides additional opportunities for growth," DeMuth said in a statement.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库